T1	Participants 173 278	elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.
T2	Participants 452 517	elderly patients with advanced, low-grade non-Hodgkin's lymphoma.
T3	Participants 675 779	One hundred and fifty-five patients were randomized, 144 were evaluable for safety and 142 for response.
